Key result
Thrombolysis is linked to ~95% lower 90-day mortality vs anticoagulation alone in higher-risk PE.
Why the study?
Bleeding risk limits systemic thrombolysis in intermediate-high-risk pulmonary embolism, and real-world data on catheter-directed therapies and multidisciplinary Pulmonary Embolism Response Teams remain limited.
Does thrombolysis reduce mortality compared to anticoagulation alone in patients with acute high and intermediate-high risk pulmonary embolism?
Population
114 patients with acute high and intermediate-high risk PE at a tertiary referral center
Comparison
Anticoagulation, systemic thrombolysis, or catheter-directed therapy
Design
Retrospective cohort study
Follow-up
90 days
Authors
Loading...
Thrombolytics may improve survival in this cohort; leaves open confirmation in randomized trials before practice change.
Cohort (n=114)
No
Does thrombolysis reduce mortality compared to anticoagulation alone in patients with acute high and intermediate-high risk pulmonary embolism?
Effect estimate: OR 0.05
p-value: p=0.022
In a real-world cohort of high and intermediate-high risk PE patients, thrombolysis was associated with a significant reduction in 90-day mortality (OR 0.05) and a low rate of major bleeding (2%).
Batum et al. (2026) conducted a cohort in Acute high and intermediate-high risk pulmonary embolism (n=114). Thrombolysis vs. Anticoagulation alone was evaluated on All-cause mortality and bleeding events (OR 0.05, p=0.022). Thrombolytic therapy was strongly protective against 90-day mortality in high and intermediate-high risk pulmonary embolism (OR 0.05, p=0.022), with major bleeding occurring in only 2% of cases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: